西格列他唑治疗伴高甘油三酯血症和胰岛素抵抗的MASLD:一项II期随机双盲安慰剂对照研究
这项II期多中心随机双盲安慰剂对照研究纳入104例伴高甘油三酯血症和胰岛素抵抗的MASLD患者,按2:2:1随机接受西格列他唑48 mg、64 mg或安慰剂每日一次治疗18周。主要终点为第18周MRI-PDFF测定的肝脂肪含量百分比变化,西格列他唑48 mg组和64 mg组较基线分别下降28.1%和39.5%,均显著优于安慰剂组,且耐受性良好。
要点
- 西格列他唑48 mg和64 mg组第18周肝脂肪含量较基线分别下降28.1%和39.5%,安慰剂组下降3.2%。
- 与安慰剂相比,48 mg组肝脂肪含量差异为-24.9%(p<0.05),64 mg组为-36.3%(p<0.001)。
- 西格列他唑还显著改善ALT、AST和γ-GT等肝损伤相关生物标志物,两种剂量耐受性良好。
核心结论
- 西格列他唑显著降低伴高甘油三酯血症和胰岛素抵抗的MASLD患者的肝脂肪含量,呈剂量依赖性效应,安全性良好。
研究设计与样本
- II期多中心、随机、双盲、安慰剂对照研究,纳入104例伴高甘油三酯血症和胰岛素抵抗的MASLD患者,按2:2:1随机接受西格列他唑48 mg、64 mg或安慰剂每日一次治疗18周。
主要发现
- 第18周肝脂肪含量较基线百分比变化:48 mg组-28.1%(95%CI -37.5至-18.7),64 mg组-39.5%(95%CI -49.0至-30.0),安慰剂组-3.2%(95%CI -16.8至10.4)。
- 与安慰剂相比的差异:48 mg组-24.9%(p<0.05),64 mg组-36.3%(p<0.001)。
- 西格列他唑显著改善ALT、AST和γ-GT等肝损伤相关生物标志物;肝纤维化指标、血脂参数、胰岛素抵抗和代谢综合征呈改善趋势。
- 两种剂量西格列他唑均耐受性良好,大多数不良事件为轻至中度。
关键数值与推荐
- 主要终点为第18周MRI-PDFF测定的肝脂肪含量百分比变化。
- 48 mg组较基线变化-28.1%(95%CI -37.5至-18.7),64 mg组-39.5%(95%CI -49.0至-30.0),安慰剂组-3.2%(95%CI -16.8至10.4)。
- 与安慰剂差异:48 mg组-24.9%(p<0.05),64 mg组-36.3%(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress to severe forms such as metabolic dysfunction-associated steatohepatitis (MASH). Effective treatments for MASH are urgently needed. This study aimed to evaluate the efficacy and safety of chiglitazar, a PPAR pan-agonist, in MASLD with hypertriglyceridemia and insulin resistance. APPROACH AND RESULTS: In this phase II multicenter, randomized, double-blind and placebo-controlled study, 104 patients with MASLD with hypertriglyceridemia and insulin resistance were randomized 2:2:1 to receive 48 mg, 64 mg of chiglitazar, or placebo once daily for 18 weeks. The primary endpoint was the percentage change in liver fat content measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) at week 18. Chiglitazar significantly reduced liver fat content, with percentage change from baseline at week 18 of -28.1% (95% CI -37.5 to -18.7) in the 48 mg group and -39.5% (95% CI -49.0 to -30.0) in the 64 mg group, compared with -3.2% (95% CI -16.8 to 10.4) in placebo group. The differences compared with placebo were -24.9% ( p <0.05) for the 48 mg group and -36.3% ( p <0.001) for the 64 mg group. Chiglitazar also significantly improved liver injury-related biomarkers such as ALT, AST, and γ-GT. Liver fibrosis indicators, lipid parameters, insulin resistance, and metabolic syndrome showed an improved trend. Both doses of chiglitazar were well tolerated, with most adverse events being mild to moderate. CONCLUSIONS: Chiglitazar significantly reduced liver fat content in MASLD with hypertriglyceridemia and insulin resistance, with a dose-dependent effect and a favorable safety profile.
引用
- Sun Y, Wu C, Xin G, et al. Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study. Hepatology. 2025. PMID: 40720744. doi:10.1097/HEP.0000000000001475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。